Overcoming Cancers Resistant to HER-2 Antibodies (Hardcover)


Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.

R3,263
List Price R3,413

Or split into 4x interest-free payments of 25% on orders over R50
Learn more

Discovery Miles32630
Mobicred@R306pm x 12* Mobicred Info
Free Delivery
Delivery AdviceShips in 9 - 15 working days


Toggle WishListAdd to wish list
Review this Item

Product Description

Overcoming Cancers Resistant to HER-2 Antibodies provides general updated information on the resistance of various human cancers to anti-HER2 therapeutic antibodies. The book also discusses the description of various sensitizing agents that can reverse resistance when used in combination with anti-HER2 antibodies. There have been a lot of reports in which the treatment with anti-HER2 antibodies for various cancers has resulted in clinical responses; however, there have been also subsets of cancer patients who did not respond initially, and several responding patients developed resistance following treatments. Sections cover Lapatinib, Ganetespib, Paclitaxel, Celecoxib, Emantasine, Liposomal Doxorubicin, and Kinase Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of the biomedical field interested in fighting cancer resistance to HER-2 antibodies.

Customer Reviews

No reviews or ratings yet - be the first to create one!

Product Details

General

Imprint

Academic Press Inc

Country of origin

United States

Series

Breaking Tolerance to Antibody-Mediated Immunotherapy

Release date

April 2020

Availability

Expected to ship within 9 - 15 working days

First published

2024

Editors

Dimensions

234 x 191mm (L x W)

Format

Hardcover

Pages

250

ISBN-13

978-0-12-816408-2

Barcode

9780128164082

Categories

LSN

0-12-816408-5



Trending On Loot